The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population

被引：0

作者：

Pei-Yin Pan

Meei-Shyuan Lee

Chin-Bin Yeh

机构：

[1] Tri-Service General Hospital,Department of Psychiatry

[2] National Defense Medical Center,undefined

[3] School of Public Health,undefined

[4] National Defense Medical Center,undefined

来源：

BMC Psychiatry | / 15卷

关键词：

Schizophrenia; Quetiapine XR; Antipsychotic agents; Drug switching; Chinese population;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Effect of Food on the Pharmacokinetics of Once-Daily Cyclobenzaprine Extended-Release 30 mg A Randomized, Open-Label, Crossover, Single-Centre Study
Darwish, Mona
Xie, Fang
CLINICAL DRUG INVESTIGATION, 2009, 29 (03) : 145 - 152
[42] Effect of Food on the Pharmacokinetics of Once-Daily Cyclobenzaprine Extended-Release 30 mgA Randomized, Open-Label, Crossover, Single-Centre Study
Mona Darwish
Fang Xie
Clinical Drug Investigation, 2009, 29 : 145 - 152
[43] Safety and Tolerability of Extended-Release Memantine (Once Daily, 28 mg) in Patients with Moderate to Severe Alzheimer's Disease: An Open-Label Extension Study
Alva, Gustavo
Grossberg, George T.
Manes, Facundo
Allegri, Ricardo
Guttierez Robledo, Luis Miguel
Gloger, Sergio
Xie, Lei
Jia, Xinwei Daniel
Perhach, James L.
Graham, Stephen M.
NEUROLOGY, 2010, 74 (09) : A394 - A395
[44] The Efficacy and Tolerability of Once-Daily Extended Release Quetiapine Fumarate in Hospitalized Patients with Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Study
Lindenmayer, Jean-Pierre
Brown, David
Liu, Sherry
Brecher, Martin
Meulien, Didier
PSYCHOPHARMACOLOGY BULLETIN, 2008, 41 (03) : 11 - 35
[45] Study of Once-Daily Levemir (SOLVE™): Safety and Efficacy of Once-Daily Insulin Detemir in Routine Clinical Practice in Chinese Patients With Type 2 Diabetes
Pan, Changyu
Lu, Juming
Gao, Zhengnan
DIABETES, 2012, 61 : A616 - A616
[46] Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain
Taber, Louise
Lynch, Shau Yu
He, Ellie
Ripa, Steven R.
POSTGRADUATE MEDICINE, 2016, 128 (01) : 23 - 33
[47] Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study
Nilsson, Anna G.
Bergthorsdottir, Ragnhildur
Burman, Pia
Dahlqvist, Per
Ekman, Bertil
Engstrom, Britt Eden
Ragnarsson, Oskar
Skrtic, Stanko
Wahlberg, Jeanette
Achenbach, Heinrich
Uddin, Sharif
Marelli, Claudio
Johannsson, Gudmundur
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2017, 176 (06) : 715 - 725
[48] Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies
Meulien, Didier
Huizar, Karin
Brecher, Martin
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2010, 25 (02) : 103 - 115
[49] A randomised, placebo-controlled study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD)
Montgomery, S.
Cutler, A.
Lazarus, A.
Schollin, M.
Brecher, M.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2007, 11 (04) : 332 - 333
[50] Efficacy and safety of once-daily dexmethylphenidate extended-release capsules in pediatric patients with attention-deficit disorder
Greenhill, LL
Litt, F
Jiang, H
Guerra, Y
Muniz, R
ANNALS OF NEUROLOGY, 2004, 56 : S107 - S107

← 1 2 3 4 5 →